|
- AstraZeneca | Cafepharma Message Boards | Pharma Sales, Device Sales . . .
Anonymous board for AstraZeneca
- AstraZeneca | Cafepharma
AstraZeneca’s quarterly revenue crossed the $15-billion mark for the first time, giving renewed hope to the company's target of reaching $80 billion in annual sales by the end of the decade "The strong underlying momentum across our business…sets us up well to sustain growth through 2026 and has us on track to deliver our 2030 ambition," remarked CEO Pascal Soriot on Thursday
- November 6 2025 - With 2030 ambitions in view, AstraZeneca’s quarterly . . .
With 2030 ambitions in view, AstraZeneca’s quarterly revenue passes $15B for first timeAstraZeneca boardEli Lilly links amylin agonist to 20% weight loss, sparking charge into phase 3Eli Lilly boardNovartis’ Pluvicto heavywork proves radiopharma can succeedNovartis boardJ J adds first new indication for Caplyta since takeover
- Pharma Biotech Companies | Cafepharma Message Boards | Pharma Sales . . .
Anonymous discussion boards for pharmaceutical and biotech companies
- Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Anonymous discussion boards for pharmaceutical sales, medical device sales, lab diagnostics sales
- Fasenra | Cafepharma
AstraZeneca's Fasenra (benralizumab) has recently been approved by the FDA for treating severe asthma in children aged 6 to 11 with the eosinophilic phenotype A phase III clinical trial is now underway to test the effectiveness of Fasenra in COPD
- AstraZenecas Fasenra (benralizumab) Fails Ph III Trial for COPD
AstraZeneca and MedImmune, announced on 5 11 18 top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) The trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with COPD
- Cafepharma News
Latest news and updates on pharmaceutical and medical sales, including breakthrough treatments and industry trends
|
|
|